How SYK and ZAP70 proteins shape which immune cells survive
SYK and ZAP70 kinases in lymphocyte selection
Researchers are looking at whether two related proteins, SYK and ZAP70, change how the immune system removes self‑reactive or pre‑cancerous B and T cells in people with autoimmune diseases and B‑cell cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11300935 on NIH RePORTER |
What this research studies
This research focuses on two enzymes, SYK and ZAP70, that control signaling in B and T lymphocytes and influence which cells are kept or deleted. The team uses genetic mouse models that can turn ZAP70 on or off in developing B cells, together with laboratory studies of signaling pathways, to see how ZAP70 interferes with SYK‑dependent calcium signaling. They also examine human tumor and patient samples to document abnormal ZAP70 expression in B‑cell malignancies. The approach aims to link molecular mechanisms to disease processes that allow autoreactive or pre‑malignant cells to survive.
Who could benefit from this research
Good fit: People with B‑cell cancers (B‑ALL, CLL, MCL) or autoimmune conditions involving B cells would be the most relevant candidates for sample donation or future clinical studies.
Not a fit: People without B‑ or T‑cell immune disorders or cancers are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, the findings could point to new ways to prevent or treat autoimmune diseases and B‑cell leukemias by targeting SYK/ZAP70 signaling.
How similar studies have performed: Previous laboratory and mouse studies from this group and others have shown that ZAP70 is often present in pre‑germinal center B‑cell malignancies and that its expression can accelerate disease in animal models.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Muschen, Markus — Yale University
- Study coordinator: Muschen, Markus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.